Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 148
Filter
1.
Eur J Med Chem ; 213: 113168, 2021 Mar 05.
Article in English | MEDLINE | ID: mdl-33508480

ABSTRACT

Novel triterpene derivatives were prepared and evaluated in salsolinol (SAL)- and glutamate (Glu)-induced models of neurodegeneration in neuron-like SH-SY5Y cells. Among the tested compounds, betulin triazole 4 bearing a tetraacetyl-ß-d-glucose substituent showed a highly potent neuroprotective effect. Further studies revealed that removal of tetraacetyl-ß-d-glucose part (free triazole derivative 10) resulted in strong neuroprotection in the SAL model at 1 µM, but this derivative suffered from cytotoxicity at higher concentrations. Both compounds modulated oxidative stress and caspase-3,7 activity, but 10 showed a superior effect comparable to the Ac-DEVD-CHO inhibitor. Interestingly, while both 4 and 10 outperformed the positive controls in blocking mitochondrial permeability transition pore opening, only 4 demonstrated potent restoration of the mitochondrial membrane potential (MMP) in the model. Derivatives 4 and 10 also showed neuroprotection in the Glu model, with 10 exhibiting the strongest oxidative stress reducing effect among the tested compounds, while the neuroprotective activity of 4 was probably due recovery of the MMP.


Subject(s)
Glutamic Acid/metabolism , Isoquinolines/antagonists & inhibitors , Models, Biological , Neuroprotective Agents/pharmacology , Triazoles/pharmacology , Triterpenes/pharmacology , Cell Line, Tumor , Cell Survival/drug effects , Dose-Response Relationship, Drug , Humans , Isoquinolines/pharmacology , Membrane Potential, Mitochondrial/drug effects , Molecular Structure , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/chemistry , Oxidative Stress/drug effects , Structure-Activity Relationship , Triazoles/chemistry , Triterpenes/chemical synthesis , Triterpenes/chemistry
2.
Invest Ophthalmol Vis Sci ; 61(2): 1, 2020 02 07.
Article in English | MEDLINE | ID: mdl-32031573

ABSTRACT

Purpose: This study aimed to explore the role of the protein kinase A (PKA) pathway in proliferative vitreoretinopathy (PVR) and the effect of the PKA inhibitor H89 on experimental PVR. Methods: Epiretinal membranes (ERMs) were acquired from PVR patients and analyzed by frozen-section immunofluorescence. An in vivo model was developed by intravitreal injecting rat eyes with ARPE-19 cells and platelet-rich plasma, and changes in eye structures and vision function were observed. An in vitro epithelial-mesenchymal transition (EMT) cell model was established by stimulating ARPE-19 cells with transforming growth factor (TGF)-ß. Alterations in EMT-related genes and cell function were detected. Mechanistically, PKA activation and activity were explored to assess the relationship between TGF-ß1 stimulation and the PKA pathway. The effect of H89 on the TGF-ß-Smad2/3 pathway was detected. RNA sequencing was used to analyze gene expression profile changes after H89 treatment. Results: PKA was activated in human PVR membranes. In vivo, H89 treatment protected against structural changes in the retina and prevented decreases in electroretinogram b-wave amplitudes. In vitro, H89 treatment inhibited EMT-related gene alterations and partially reversed the functions of the cells. TGF-ß-induced PKA activation was blocked by H89 pretreatment. H89 did not affect the phosphorylation or nuclear translocation of regulatory Smad2/3 but increased the expression of inhibitory Smad6. Conclusions: PKA pathway activation is involved in PVR pathogenesis, and the PKA inhibitor H89 can effectively inhibit PVR, both in vivo and in vitro. Furthermore, the protective effect of H89 is related to an increase in inhibitory Smad6.


Subject(s)
Isoquinolines/antagonists & inhibitors , Sulfonamides/antagonists & inhibitors , Vitreoretinopathy, Proliferative/drug therapy , Aged , Animals , Cells, Cultured , Cyclic AMP-Dependent Protein Kinase Catalytic Subunits/metabolism , Electroretinography , Epiretinal Membrane/metabolism , Epithelial Cells/metabolism , Female , Humans , Isoquinolines/pharmacology , MAP Kinase Signaling System/physiology , Male , Middle Aged , Retinal Pigment Epithelium/drug effects , Smad Proteins/physiology , Sulfonamides/pharmacology , Transforming Growth Factor beta/antagonists & inhibitors
3.
Domest Anim Endocrinol ; 58: 97-103, 2017 01.
Article in English | MEDLINE | ID: mdl-27792889

ABSTRACT

This study tested the hypothesis that salsolinol, a derivative of dopamine, affects GnRH and LH secretion in lactating sheep. In the in vivo experiment, the structural analogue of salsolinol, 1-methyl-3,4-dihydroisoquinoline (1-MeDIQ), was infused into the infundibular nucleus-median eminence of sheep at the fifth wk of lactation to antagonize salsolinol's action. Simultaneously, cerebrospinal fluid from the third brain ventricle, to determine GnRH concentration, and plasma samples, to measure LH concentration, were collected. In the in vitro experiment, the anterior pituitary (AP) explants from weaned sheep were incubated in culture medium containing 2 doses of salsolinol, 20 and 100 µg/mL (S20 and S100, respectively). The concentration of LH in the collected media and relative expression of LHß subunit messenger RNA in the AP explants were determined. No significant difference was found in mean GnRH concentration in response to 1-MeDIQ infusion, but both mean plasma LH concentration and LH pulse frequency increased significantly (P < 0.001 and P < 0.05, respectively) compared with those in controls. Significantly higher LH concentrations occurred during the first (P < 0.001), second (P < 0.001), and fourth (P < 0.05) h of 1-MeDIQ infusion. In the in vitro study, both the S20 and S100 doses of salsolinol caused a significant decrease in the mean medium LH concentration compared with that in the control (P < 0.01 and P < 0.001, respectively). Salsolinol had no effect on the relative LHß subunit messenger RNA expression in the incubated tissue. In conclusion, salsolinol is a potential inhibitor of the secretory activity of the gonadotropic axis in lactating sheep, at least at the AP level. Although no significant changes in GnRH release were directly confirmed, an increase in the frequency of LH pulses does not allow to exclude the central action of salsolinol.


Subject(s)
Gonadotropin-Releasing Hormone/antagonists & inhibitors , Isoquinolines/administration & dosage , Lactation/physiology , Luteinizing Hormone/antagonists & inhibitors , Sheep/physiology , Animals , Arcuate Nucleus of Hypothalamus/drug effects , Culture Media, Conditioned/analysis , Female , Gene Expression , Gonadotropin-Releasing Hormone/cerebrospinal fluid , Gonadotropin-Releasing Hormone/metabolism , Isoquinolines/antagonists & inhibitors , Luteinizing Hormone/analysis , Luteinizing Hormone/blood , Luteinizing Hormone, beta Subunit/genetics , Median Eminence/drug effects , Pituitary Diseases/metabolism , RNA, Messenger/analysis , Tissue Culture Techniques
4.
Theriogenology ; 86(8): 1931-8, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27393219

ABSTRACT

The aim of the study was to test the hypothesis that salsolinol, a derivative of dopamine, is involved in the regulation of hypothalamic-pituitary gonadotropic (GnRH/LH) axis activity in lactating sheep. In the first experiment performed on sheep during the fifth week of lactation, a structural analogue of salsolinol (1-MeDIQ) was infused into the third brain ventricle (IIIv) to antagonize its action within the central nervous system (CNS). A push-pull perfusion of the infundibular nucleus/median eminence was performed simultaneously, and blood samples were collected from the jugular vein. In the second experiment, sheep received infusions of salsolinol into the IIIv, 48 hours after the weaning of their 8-week-old lambs. Blood samples were collected during the experimental periods, and the anterior pituitary (AP) tissue was dissected immediately after the end of the experiment. Perfusate GnRH concentration (experiment 1), plasma LH concentration (experiments 1 and 2), and relative LHß mRNA levels in the AP tissue (experiment 2) were assayed. Blocking of salsolinol action in the CNS of lactating sheep caused a significant (P < 0.001) decrease in the perfusate GnRH concentrations in comparison with controls. Treatment with 1-MEDIQ also significantly decreased (P < 0.001) the LH concentration in the blood plasma. In turn, salsolinol infused 48 hours after lamb weaning significantly (P < 0.001) increased plasma LH concentration, reflected in the significant (P < 0.05) increase in the amplitude of LH pulses in the treated sheep as compared to the control animals. There was no significant difference in the relative levels of LHß-subunit mRNA in the AP between control and salsolinol-infused sheep. The results lead to a conclusion that salsolinol affects the secretory activity of the GnRH/LH axis in sheep during lactation. Whether salsolinol infused into the IIIv evokes this stimulatory effect by itself or by modulation of other regulatory systems needs to be clarified.


Subject(s)
Gonadotropin-Releasing Hormone/metabolism , Hypothalamo-Hypophyseal System/metabolism , Isoquinolines/pharmacology , Luteinizing Hormone/metabolism , Sheep/physiology , Animals , Female , Hypothalamo-Hypophyseal System/drug effects , Injections, Intraventricular/veterinary , Isoquinolines/administration & dosage , Isoquinolines/antagonists & inhibitors , Lactation/physiology
5.
Curr Opin Anaesthesiol ; 28(4): 403-10, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26087274

ABSTRACT

PURPOSE OF REVIEW: This review summarizes recent progress in the development of new muscle relaxants that are inactivated by cysteine, and considers the evolving paradigm of selective relaxant binding or degrading agents that can reverse neuromuscular blockade at any time. RECENT FINDINGS: The benzylisoquinoline compound gantacurium is a nondepolarizing muscle relaxant with an ultrashort duration largely determined by the rapid rate at which endogenous L-cysteine binds to, and permanently inactivates, the molecule. Although the clinical development of gantacurium has been hampered by modest histamine release, preclinical studies demonstrating that the drug can be rapidly reversed by injecting L-cysteine led to the development of CW002, an intermediate duration molecule that can also be reversed at any time by L-cysteine injection. Clinical trials with CW002 are now underway. The ability to reverse complete paralysis with cysteine dovetails with the established selective aminosteroid binding agent sugammadex, and the recently described universal relaxant binding agent calabadion. Taken together, the concept of rapid reversal at any time raises the question of whether an ultrashort nondepolarizing drug is needed if safe and cost-effective relaxant binding agents are available. SUMMARY: The gantacurium derivative CW002 is an intermediate duration, nondepolarizing, cysteine-inactivated, neuromuscular blocking drug currently in clinical trials. Like sugammadex reversal of rocuronium, CW002 can be reversed at any time by cysteine injection.


Subject(s)
Cysteine/therapeutic use , Isoquinolines/antagonists & inhibitors , Isoquinolines/therapeutic use , Neuromuscular Blockade/methods , Neuromuscular Nondepolarizing Agents/antagonists & inhibitors , Neuromuscular Nondepolarizing Agents/therapeutic use , Humans , Sugammadex , gamma-Cyclodextrins/antagonists & inhibitors , gamma-Cyclodextrins/therapeutic use
6.
J Pharmacol Sci ; 127(1): 135-44, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25704029

ABSTRACT

Previous studies show that several pathways are involved in sanguinarine-induced apoptotic cell death, including AKT downregulation, inhibition of NF-kB activation, mediation of ROS production, downregulation of anti-apoptosis proteins XIAP and cIAP-1, upregulation of BAX, and downregulation of BCL2. In this study, we found out that the quenching of ROS generation by N-acetyl-l-cysteine (NAC), a scavenger of ROS, reversed sanguinarine-induced apoptosis effects, also we found out that sanguinarine-induced rat hepatic stellate T6 cells (HSC-T6 cells) apoptosis was correlated with the generation of increased ROS, which was followed by the activation of caspase-8 (-3, -6, and -9), and the decreasing in the miltochondrial membrane potential (MMP) and the down-regulation of anti-apoptotic protein Bcl-2. It is not clear whether BCL2's downregulation relates to its promoter methylation and miR-15a/16-1 expression which can bind to BCL2 3'-UTR (un-translation reagon). We showed that sanguinarine-induced down regulation of BCL2 was associated with the increased methylation rate of BCL2 promotor district and the increased expression of miR-15a/16-1. HSC-T6 cells treatment with 5-Aza-2'-deoxycytidine (5'-Aza-CdR) impeded sanguinarine-induced BCL2 promotor district methylation and recovered BCL2's expression. Over expression of BCL2 using pEGFP-N1 vector decreased sanguinarine-induced HSC-T6 cells apoptotic death significantly but not completely. These observations clearly showed that BCL2 down regulation was associated with its promoter methylation and miR-15a/16-1 upregulation in sanguinarine-induced Rat HSC-T6 cells.


Subject(s)
Apoptosis/drug effects , Benzophenanthridines/pharmacology , Isoquinolines/pharmacology , MicroRNAs/metabolism , Promoter Regions, Genetic/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Animals , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Benzophenanthridines/antagonists & inhibitors , Cell Line , Cell Survival/drug effects , Decitabine , Down-Regulation , Isoquinolines/antagonists & inhibitors , Membrane Potential, Mitochondrial/drug effects , Methylation/drug effects , Rats , Reactive Oxygen Species/metabolism , Up-Regulation
7.
J Neuroendocrinol ; 26(12): 844-52, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25205344

ABSTRACT

In mammals, the responsiveness of the hypothalamic-pituitary-adrenal (HPA) axis to stress is reduced during lactation and this mainly results from suckling by the offspring. The suckling stimulus causes a release of the hypothalamic 1-metyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) (a derivative of dopamine), one of the prolactin-releasing factors. To investigate the involvement of salsolinol in the mechanism suppressing stress-induced HPA axis activity, we conducted a series of experiments on lactating sheep, in which they were treated with two kinds of isolation stress (isolation from the flock with lamb present or absent), combined with suckling and/or i.c.v infusion of salsolinol and 1-methyl-3,4-dihydro-isoqinoline (1-MeDIQ; an antagonistic analogue of salsolinol). Additionally, a push-pull perfusion of the infundibular nucleus/median eminence (IN/ME) and blood sample collection with 10-min intervals were performed during the experiments. Concentrations of perfusate corticotrophin-releasing hormone (CRH) and catecholamines (noradrenaline, dopamine and salsolinol), as well as concentrations of plasma adenocorticotrophic hormone (ACTH), cortisol and prolactin, were assayed. A significant increase in perfusate noradrenaline, plasma ACTH and cortisol occurred in response to both kinds of isolation stress. Suckling and salsolinol reduced the stress-induced increase in plasma ACTH and cortisol concentrations. Salsolinol also significantly reduced the stress-induced noradrenaline and dopamine release within the IN/ME. Treatment with 1-MeDIQ under the stress conditions significantly diminished the salsolinol concentration and increased CRH and cortisol concentrations. Stress and salsolinol did not increase the plasma prolactin concentration, in contrast to the suckling stimulus. In conclusion, salsolinol released in nursing sheep may have a suppressing effect on stress-induced HPA axis activity and peripheral prolactin does not appear to participate in its action.


Subject(s)
Animals, Suckling/physiology , Hypothalamo-Hypophyseal System/drug effects , Hypothalamo-Hypophyseal System/physiology , Isoquinolines/pharmacology , Lactation/physiology , Pituitary-Adrenal System/drug effects , Pituitary-Adrenal System/physiology , Stress, Psychological/metabolism , Adrenocorticotropic Hormone/blood , Animals , Arcuate Nucleus of Hypothalamus/drug effects , Arcuate Nucleus of Hypothalamus/metabolism , Catecholamines/metabolism , Corticotropin-Releasing Hormone/metabolism , Female , Hydrocortisone/blood , Isoquinolines/antagonists & inhibitors , Lactation/metabolism , Male , Median Eminence/drug effects , Median Eminence/metabolism , Prolactin/blood , Sheep, Domestic , Social Isolation/psychology , Stress, Psychological/physiopathology
8.
Anim Sci J ; 85(4): 461-7, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24329779

ABSTRACT

The aim of the present study was to clarify the effects of hypothalamic dopamine (DA) on salsolinol (SAL)-induced prolactin (PRL) release in goats. The PRL-releasing response to an intravenous (i.v.) injection of SAL was examined after treatment with augmentation of central DA using carbidopa (carbi) and L-dopa in male goats under 8-h (8 h light, 16 h dark) or 16-h (16 h light, 8 h dark) photoperiod conditions. The carbi and L-dopa treatments reduced basal PRL concentrations in the 16-h photoperiod group (P < 0.05), while a reduction was not observed in the 8-h photoperiod group. The mean basal plasma PRL concentration in the control group for the 8-h photoperiod was lower than that for the 16-h photoperiod (P < 0.05). SAL significantly stimulated the release of PRL promptly after the injection in both the 8- and 16-h photoperiod groups (P < 0.05). PRL-releasing responses for the 16-h photoperiod were greater than those for the 8-h photoperiod (P < 0.05). The carbi and L-dopa treatments blunted SAL-induced PRL release in both the 8- and 16-h photoperiods (P < 0.05). These results indicate that hypothalamic DA blunts the SAL-induced release of PRL in male goats, regardless of the photoperiod, which suggests that both SAL and DA are involved in regulating the secretion of PRL in goats.


Subject(s)
Carbidopa/pharmacology , Dopamine/physiology , Goats/physiology , Hypothalamus/physiology , Isoquinolines/pharmacology , Levodopa/pharmacology , Prolactin/metabolism , Animals , Injections, Intravenous , Isoquinolines/administration & dosage , Isoquinolines/antagonists & inhibitors , Male , Photoperiod , Stimulation, Chemical , Time Factors
9.
Br J Anaesth ; 112(3): 498-505, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24240315

ABSTRACT

BACKGROUND: The routine use of neuromuscular blocking agents reduces the occurrence of unacceptable surgical conditions. In some surgeries, such as retroperitoneal laparoscopies, deep neuromuscular block (NMB) may further improve surgical conditions compared with moderate NMB. In this study, the effect of deep NMB on surgical conditions was assessed. METHODS: Twenty-four patients undergoing elective laparoscopic surgery for prostatectomy or nephrectomy were randomized to receive moderate NMB (train-of-four 1-2) using the combination of atracurium/mivacurium, or deep NMB (post-tetanic count 1-2) using high-dose rocuronium. After surgery, NMB was antagonized with neostigmine (moderate NMB), or sugammadex (deep NMB). During all surgeries, one surgeon scored the quality of surgical conditions using a five-point surgical rating scale (SRS) ranging from 1 (extremely poor conditions) to 5 (optimal conditions). Video images were obtained and 12 anaesthetists rated a random selection of images. RESULTS: Mean (standard deviation) SRS was 4.0 (0.4) during moderate and 4.7 (0.4) during deep NMB (P<0.001). Moderate block resulted in 18% of scores at the low end of the scale (Scores 1-3); deep block resulted in 99% of scores at the high end of the scale (Scores 4 and 5). Cardiorespiratory conditions were similar during and after surgery in both groups. Between anaesthetists and surgeon, there was poor agreement between scores of individual images (average κ statistic 0.05). CONCLUSIONS: Application of the five-point SRS showed that deep NMB results in an improved quality of surgical conditions compared with moderate block in retroperitoneal laparoscopies, without compromise to the patients' peri- and postoperative cardiorespiratory conditions. Trial registration The study was registered at clinicaltrials.gov under number NCT01361149.


Subject(s)
Laparoscopy , Neuromuscular Blockade , Neuromuscular Blocking Agents , Adult , Aged , Androstanols/administration & dosage , Androstanols/antagonists & inhibitors , Anesthesia, Intravenous , Anesthetics, Intravenous , Consciousness Monitors , Data Interpretation, Statistical , Electric Stimulation , Electromyography , Endpoint Determination , Hemodynamics , Humans , Isoquinolines/administration & dosage , Isoquinolines/antagonists & inhibitors , Middle Aged , Mivacurium , Monitoring, Intraoperative , Muscle Contraction/physiology , Neuromuscular Blocking Agents/antagonists & inhibitors , Neuromuscular Nondepolarizing Agents/administration & dosage , Neuromuscular Nondepolarizing Agents/antagonists & inhibitors , Propofol , Rocuronium , Sample Size , Sufentanil , Sugammadex , Video Recording , gamma-Cyclodextrins
10.
Anim Sci J ; 83(1): 63-7, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22250741

ABSTRACT

The secretion of prolactin (PRL) is under the dominant and tonic inhibitory control of dopamine (DA); however, we have recently found that salsolinol (SAL), an endogenous DA-derived compound, strongly stimulated the release of PRL in ruminants. The aim of the present study was to clarify the inhibitory effect of DA on the SAL-induced release of PRL in ruminants. The experiments were performed from late June to early July. Male goats were given a single intravenous (i.v.) injection of SAL (5mg/kg body weight (BW)), a DA receptor antagonist (sulpiride, 0.1mg/kg BW), or thyrotropin-releasing hormone (TRH, 1µg/kg BW) before and after treatment with a DA receptor agonist (bromocriptine), and the effect of DA on SAL-induced PRL release was compared to that on sulpiride- or TRH-induced release. Bromocriptine completely inhibited the SAL-induced release of PRL (P<0.05), and the area under the response curve (AUC) for a 120-min period after the treatment with bromocriptine was 1/28 of that for before the treatment (P<0.05). Bromocriptine also completely inhibited the sulpiride-induced release (P<0.05). The AUC post-treatment was 1/17 that of pre-treatment with bromocriptine (P<0.05). Bromocriptine also inhibited the TRH-induced release (P<0.05), though not completely. The AUC post-treatment was 1/3.8 that of pre-treatment (P<0.05). These results indicate that DA inhibits the SAL-induced release of PRL in male goats, and suggest that SAL and DA are involved in regulating the secretion of PRL. They also suggest that in terms of the regulatory process for the secretion of PRL, SAL resembles sulpiride but differs from TRH.


Subject(s)
Bromocriptine/pharmacology , Dopamine Agonists/pharmacology , Goats/metabolism , Isoquinolines/antagonists & inhibitors , Prolactin/metabolism , Animals , Dopamine/pharmacology , Dopamine/physiology , Isoquinolines/pharmacology , Male , Rumen/metabolism , Stimulation, Chemical , Sulpiride/antagonists & inhibitors , Sulpiride/pharmacology , Thyrotropin-Releasing Hormone/antagonists & inhibitors , Thyrotropin-Releasing Hormone/pharmacology
11.
Toxicol Lett ; 205(3): 285-92, 2011 Sep 10.
Article in English | MEDLINE | ID: mdl-21722720

ABSTRACT

In this study, we examined the cytotoxic effects of sanguinarine, a phytoalexin with antimicrobial, anti-oxidant, anti-inflammatory and pro-apoptotic effects, on the blastocyst stage of mouse embryos, subsequent embryonic attachment and outgrowth in vitro and in vivo implantation via embryo transfer. Blastocysts treated with 0.5-2 µM sanguinarine exhibited significantly increased apoptosis and a corresponding decrease in total cell number. Notably, the implantation success rates of blastocysts pretreated with sanguinarine were lower than that of their control counterparts. Moreover, in vitro treatment with 0.5-2 µM sanguinarine was associated with increased resorption of post-implantation embryos and decreased fetal weight. Our results collectively indicate that sanguinarine induces apoptosis and retards early post-implantation development in vitro and in vivo. In addition, sanguinarine induces apoptotic injury effects on mouse blastocysts through intrinsic and extrinsic apoptotic signaling processes to impair sequent embryonic development. However, the extent to which sanguinarine exerts teratogenic effects on early human development is not known at present, and further studies are required to establish effective protection strategies against its cytotoxic effects.


Subject(s)
Apoptosis/drug effects , Benzophenanthridines/toxicity , Blastocyst/drug effects , Embryonic Development/drug effects , Isoquinolines/toxicity , Sesquiterpenes/toxicity , Teratogens/toxicity , Animals , Benzophenanthridines/antagonists & inhibitors , Blastocyst/pathology , Blastocyst Inner Cell Mass/drug effects , Blastocyst Inner Cell Mass/pathology , Caspase Inhibitors , Cell Proliferation/drug effects , Cysteine Proteinase Inhibitors/pharmacology , Cysteine Proteinase Inhibitors/therapeutic use , Dose-Response Relationship, Drug , Ectogenesis/drug effects , Embryo Implantation/drug effects , Embryo Loss/chemically induced , Embryo Loss/drug therapy , Embryo Transfer , Female , Fetal Weight/drug effects , Isoquinolines/antagonists & inhibitors , Mice , Mice, Inbred ICR , Random Allocation , Sesquiterpenes/antagonists & inhibitors , Signal Transduction/drug effects , Phytoalexins
12.
Anesthesiology ; 113(1): 58-73, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20526187

ABSTRACT

BACKGROUND: The ultra-short-acting neuromuscular blocker gantacurium is chemically degraded in vitro by rapid adduction of L-cysteine to its central olefinic double bond. Preliminary data have suggested that exogenous (intravenous) L-cysteine abolishes gantacurium blockade. Two new analogues of gantacurium (CW 002 and CW 011) have been synthesized to undergo slower L-cysteine adduction, yielding intermediate duration. L-cysteine adduction to and antagonism of these novel agents is further defined herein. METHODS: Comparative reaction half-time for L-cysteine adduction in vitro of the three compounds was determined by high-performance liquid chromatography. ED95 for twitch inhibition in monkeys under isoflurane was calculated, and duration at approximately 4-5x ED95 was correlated with reaction half-time for adduction. Speed of L-cysteine antagonism was contrasted with anticholinesterase reversal. Potencies of CW 002 and its adduction product were compared to provide a basis for L-cysteine antagonism. RESULTS: Rate of L-cysteine adduction in vitro (reaction half-time) was 11.4 and 13.7 min for CW 002 and CW 011 versus 0.2 min for gantacurium, and was inversely related to duration of block (P < 0.0001). CW 002 and CW 011 were 3x longer acting than gantacurium (28.1 and 33.3 min vs. 10.4 min), but only half the duration of cisatracurium. The adduct of CW 002 was approximately 70x less potent than CW 002. L-cysteine (10-50 mg/kg intravenously) given 1 min after approximately 4-5x ED95 doses of all the three compounds abolished block within 2-3 min. CONCLUSIONS: L-cysteine adduction occurs at different rates by design in olefinic isoquinolinium diester neuromuscular blockers, yielding corresponding durations of action. Antagonism by exogenous L-cysteine is superior to anticholinesterases, inducing inactivation of the active molecules to restore function rapidly at any time.


Subject(s)
Cysteine/pharmacology , Isoquinolines/antagonists & inhibitors , Maleates/antagonists & inhibitors , Neuromuscular Blockade , Neuromuscular Blocking Agents/antagonists & inhibitors , Alkenes/antagonists & inhibitors , Animals , Atracurium/analogs & derivatives , Atracurium/antagonists & inhibitors , Chemical Phenomena , Cholinesterase Inhibitors/administration & dosage , Chromatography, High Pressure Liquid/methods , Dose-Response Relationship, Drug , Drug Interactions , Edrophonium/administration & dosage , Haplorhini , Macaca mulatta , Male , Neostigmine/administration & dosage , Structure-Activity Relationship
13.
Acta Neurobiol Exp (Wars) ; 70(1): 20-7, 2010.
Article in English | MEDLINE | ID: mdl-20407483

ABSTRACT

Suckling induces a GH surge simultaneously to that of prolactin, so we tested whether salsolinol, a dopamine derivative (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline), participates in the regulatory process of GH secretion in lactating sheep. A series of intracerebroventricular (i.c.v.) infusions of salsolinol, in two doses, was performed in nursing sheep, without suckling, during the fifth week of lactation. In other suckling sheep, we infused i.c.v. a structural analogue of salsolinol-1-methyl-3,4-dihydroisoqinoline (1-MeDIQ), which is able to antagonize salsolinol's action. Intracerebroventricular treatment of nursing sheep with a lower dose of salsolinol (total 50 ng) significantly increased plasma GH concentration, as compared with the concentrations noted before the infusion and in nursing controls. A higher dose of salsolinol (total 5 micrograms) did not affect GH release significantly. Intracerebroventricular treatment with 1-MeDIQ (total 300 micrograms) significantly reduced basal GH release, not affecting a pattern of GH surge in response to suckling. In conclusion, salsolinol may affect the regulatory process of GH secretion in lactating sheep, but its role seems not to be major.


Subject(s)
Growth Hormone/blood , Isoquinolines/antagonists & inhibitors , Isoquinolines/pharmacology , Lactation/drug effects , Analysis of Variance , Animals , Dose-Response Relationship, Drug , Drug Administration Routes , Female , Pregnancy , Sheep , Sucking Behavior/drug effects
14.
Anesthesiology ; 112(4): 900-9, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20234310

ABSTRACT

BACKGROUND: CW002 is a neuromuscular blocking drug that is inactivated by endogenous L-cysteine. This study determined the exogenous L-cysteine dose-response relationship for CW002 reversal along with acute cardiovascular effects and organ toxicity in dogs. METHODS: Six dogs were each studied four times during isoflurane-nitrous oxide anesthesia and recording of muscle twitch, arterial pressure, and heart rate. CW002 (0.08 mg/kg or 9 x ED95) was injected, and the time to spontaneous muscle recovery was determined. CW002 was then administered again followed 1 min later by 10, 20, 50, or 100 mg/kg L-cysteine (1 dose/experiment). After twitch recovery, CW002 was given a third time to determine whether residual L-cysteine influenced duration. Preliminary toxicology was performed in an additional group of dogs that received CW002 followed by vehicle (n = 8) or 200 mg/kg L-cysteine (n = 8). Animals were awakened and observed for 2 or 14 days before sacrificing and anatomic, biochemical, and histopathologic analyses. RESULTS: L-cysteine at all doses accelerated recovery from CW002, with both 50 and 100 mg/kg decreasing median duration from more than 70 min to less than 5 min. After reversal, duration of a subsequent CW002 dose was also decreased in a dose-dependent manner. Over the studied dose range, L-cysteine had less than 10% effect on blood pressure and heart rate. Animals receiving a single 200-mg/kg dose of L-cysteine showed no clinical, anatomic, biochemical, or histologic evidence of organ toxicity. CONCLUSION: The optimal L-cysteine dose for rapidly reversing the neuromuscular blockade produced by a large dose of CW002 in dogs is approximately 50 mg/kg, which has no concomitant hemodynamic effect. A dose of 200 mg/kg had no evident organ toxicity.


Subject(s)
Cysteine/pharmacology , Hemodynamics/drug effects , Isoquinolines/antagonists & inhibitors , Isoquinolines/pharmacology , Neuromuscular Blocking Agents/antagonists & inhibitors , Neuromuscular Blocking Agents/pharmacology , Animals , Blood Cell Count , Blood Chemical Analysis , Blood Coagulation , Blood Pressure/drug effects , Cysteine/toxicity , Dogs , Dose-Response Relationship, Drug , Heart Rate/drug effects , Indicators and Reagents , Isoquinolines/toxicity , Neuromuscular Blocking Agents/toxicity , Stroke Volume/drug effects
15.
Anesthesiology ; 112(4): 910-6, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20234311

ABSTRACT

BACKGROUND: CW002 is a novel neuromuscular blocking drug with a duration dependent on the rate of cysteine adduction to the molecule. The current study characterized the pharmacodynamics and cardiopulmonary side effects of CW002 in dogs. METHODS: In eight beagles, the dose required to produce 95% neuromuscular blockade (ED95) for CW002 was first determined and cysteine reversibility was confirmed. Five to 7 days later, incrementally larger doses were injected starting with 6.25 x ED95 and doubling the dose every 15 min. Before and after injection, blood was obtained for histamine analysis. Systemic and pulmonary arterial pressures, cardiac output, and left ventricular pressure and volume were recorded along with inspiratory pressure and pulmonary compliance. Ventricular contractility and lusitropy were indexed from pressure and volume data. RESULTS: The ED95 for CW002 from pooled data was 0.009 mg/kg. At 3 x ED95, onset time was 2.6 +/- 0.9 min and duration was 47 +/- 9 min. The duration was shortened to 3.7 +/- 0.6 min by 50 mg/kg L-cysteine injected 1 min after CW002. At 25 x ED95, CW002 reduced mean arterial pressure with concomitant decreases in systemic vascular resistance, mean pulmonary artery pressure, cardiac output, contractility, and lusitropy, beginning at 50 x ED95. However, even at a dose of 100 x ED95, the average change in any variable was less than 20%. There were no changes in pulmonary vascular resistance or ventilation mechanics at any dose, and histamine release occurred in only two of eight animals. CONCLUSIONS: CW002 is a potent neuromuscular blocking drug that at doses up to 100 x ED95 produces modest hemodynamic effects that are not associated with bronchoconstriction or consistent histamine release.


Subject(s)
Cysteine/pharmacology , Hemodynamics/drug effects , Isoquinolines/antagonists & inhibitors , Isoquinolines/pharmacology , Lung/drug effects , Neuromuscular Blocking Agents/antagonists & inhibitors , Neuromuscular Blocking Agents/pharmacology , Animals , Blood Pressure/drug effects , Data Interpretation, Statistical , Dogs , Dose-Response Relationship, Drug , Heart Rate/drug effects , Histamine Release/drug effects , Isoquinolines/toxicity , Lung Compliance/drug effects , Neuromuscular Blocking Agents/toxicity , Respiratory Function Tests , Respiratory Mechanics/drug effects
16.
Biochem Pharmacol ; 79(10): 1462-72, 2010 May 15.
Article in English | MEDLINE | ID: mdl-20096267

ABSTRACT

In this work, we aimed to build a 3D-model of NIK and to study the binding of pyrazolo[4,3-c]isoquinolines with a view to highlight the structural elements responsible for their inhibitory potency. However, in the course of this work, we unexpectedly found that the pyrazolo[4,3-c]isoquinolines initially reported as NIK inhibitors were neither inhibitors of this enzyme nor of the alternative NF-kappaB pathway, but were in fact inhibitors of another kinase, the TGF-beta activated kinase 1 (TAK1) which is involved in the classical NF-kappaB pathway.


Subject(s)
Isoquinolines/antagonists & inhibitors , NF-kappa B/antagonists & inhibitors , Pyrazoles/antagonists & inhibitors , Arthritis, Rheumatoid/metabolism , HeLa Cells , Humans , MAP Kinase Kinase Kinases/drug effects , MAP Kinase Kinase Kinases/physiology , NF-kappa B/physiology , Recombinant Proteins , Signal Transduction/drug effects , Signal Transduction/physiology , Structure-Activity Relationship
18.
ChemMedChem ; 3(7): 1118-28, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18428185

ABSTRACT

p53 has been at the centre of attention for drug design since the discovery of its growth-suppressive and pro-apoptotic activity. Herein we report the design and characterisation of a new class of isoquinolinone inhibitors of the MDM2-p53 interaction. Our identification of druglike and selective inhibitors of this protein-protein interaction included a straightforward in silico compound-selection process, a recently reported NMR spectroscopic approach for studying the MDM2-p53 interaction, and selectivity screening assays using cells with the same genetic background. The selected inhibitors were all able to induce apoptosis and the expression of p53-related genes, but only the isoquinolin-1-one-based inhibitors stabilised p53. Our NMR experiments give a persuading explanation for these results, showing that isoquinolin-1-one derivates are able to dissociate the preformed MDM2-p53 complex in vitro, releasing a folded and soluble p53. The joint application of these methods provides a framework for the discovery of protein interaction inhibitors as a promising starting point for further drug design.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Proliferation/drug effects , Enzyme Inhibitors/pharmacology , Isoquinolines/antagonists & inhibitors , Proto-Oncogene Proteins c-mdm2 , Antineoplastic Agents/chemistry , Cell Line, Tumor , Computer Simulation , Drug Design , Enzyme Inhibitors/chemistry , Humans , Inhibitory Concentration 50 , Magnetic Resonance Spectroscopy , Protein Binding , Protein Folding , Proto-Oncogene Proteins c-mdm2/antagonists & inhibitors , Proto-Oncogene Proteins c-mdm2/genetics , Proto-Oncogene Proteins c-mdm2/metabolism
19.
Vet Anaesth Analg ; 35(3): 191-200, 2008 May.
Article in English | MEDLINE | ID: mdl-18282258

ABSTRACT

OBJECTIVE: To study heart rate (HR), arterial blood pressure (BP) and autonomic nervous (AN) effects of edrophonium-atropine combinations during neuromuscular blockade (NMB) antagonism in sheep. EXPERIMENTAL DESIGN: Randomized, prospective and experimental study. ANIMALS: Seventy-eight Scottish blackface ewes; mean age: 4.5 years; mean body mass: 54 kg. METHODS: After induction with IV etomidate (0.5 mg kg(-1)) and midazolam (0.5 mg kg(-1)), anaesthesia was maintained with halothane and NMB produced with atracurium or mivacurium. In the first study (n = 53), the electrocardiographic (ECG), HR, BP and AN effects of low (40 microg kg(-1)) and high (80 microg kg(-1)) atropine doses combined with either of two edrophonium doses (0.5 or 1.0 mg kg(-1)) were investigated. These variables were also measured in a second study when edrophonium (1.0 mg kg(-1)) was administered 5 minutes before atropine (80 microg kg(-1)) and vice versa. Data were analysed using one-way within-subjects and repeated measures anova. RESULTS: In the first study, all combinations reversed NMB but significantly (p < 0.001) increased HR and BP within 2 minutes without arrhythmias. In the second study, edrophonium (1.0 mg kg(-1)) significantly increased HR and BP, saliva flow (n = 1) and lung sounds (n = 3) and caused ECG changes (n = 1). Cardiovascular changes were partially reversed by atropine (80 microg kg(-1)) administered 5 minutes later. Administered first, atropine (80 microg kg(-1)) significantly decreased HR and BP effects which were fully (HR) and partially (BP) reversed by edrophonium (1 mg kg(-1)) administered 5 minutes later. CONCLUSION AND CLINICAL RELEVANCE: The cardiovascular effects of edrophonium and atropine were opposite to those reported in humans and dogs. Edrophonium (0.5 mg kg(-1)) and atropine (80 microg kg(-1)) caused the mildest HR changes without ECG and noncardiac AN disturbances, and is recommended for the antagonism of NMB in sheep.


Subject(s)
Atropine/administration & dosage , Atropine/pharmacology , Edrophonium/administration & dosage , Edrophonium/pharmacology , Neuromuscular Blockade/veterinary , Sheep , Anesthesia/veterinary , Animals , Atracurium/antagonists & inhibitors , Atracurium/pharmacology , Blood Pressure/drug effects , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/pharmacology , Drug Therapy, Combination , Female , Heart Rate/drug effects , Isoquinolines/antagonists & inhibitors , Isoquinolines/pharmacology , Mivacurium , Muscarinic Antagonists/administration & dosage , Muscarinic Antagonists/pharmacology , Neuromuscular Blocking Agents/antagonists & inhibitors , Neuromuscular Blocking Agents/pharmacology
20.
Neurochem Int ; 52(4-5): 864-77, 2008.
Article in English | MEDLINE | ID: mdl-17996985

ABSTRACT

Memantine, a clinically used N-methyl-D-aspartate (NMDA)-receptor antagonist, has been shown to prevent apoptotic neuronal damage connected with the over-activity of NMDA receptors. In the present study, we examined the effect of memantine on staurosporine-, salsolinol- and doxorubicin-induced apoptosis in the SH-SY5Y cell line which does not possess functional NMDA receptors. Electrophysiological recordings and toxicity studies showed no response to NMDA-evoked currents in this cell line, irrespective of the stage of its neuronal differentiation. Memantine (0.1-2 microM) attenuated staurosporine-induced apoptosis as evidenced by reversal of the changes in mitochondrial membrane potential (DeltaPsi(m)) and decreased caspase-3 activity, lactate dehydrogenase (LDH) release and DNA fragmentation. Wortmannin (10 nM) and LY 294002 (10 microM) (inhibitors of phosphatidylinositol-3-kinase, PI3-K) reversed the inhibitory effect of memantine on the staurosporine-induced LDH release, suggesting that the PI3-K/Akt prosurvival pathway is a possible target for antiapoptotic action of memantine. Memantine at low micromolar concentrations also attenuated salsolinol- and doxorubicin-induced LDH release and DNA fragmentation, but only in the case of salsolinol was this effect accompanied by a decrease in caspase-3 activity. The present data indicate that memantine attenuates the toxic effects of various proapoptotic agents and the cytoprotective effect of memantine does not seem to be connected with its action on NMDA receptor but rather with its influence on intracellular pathways engaged in cellular survival/apoptotic processes.


Subject(s)
Antibiotics, Antineoplastic/antagonists & inhibitors , Antibiotics, Antineoplastic/pharmacology , Apoptosis/drug effects , Doxorubicin/antagonists & inhibitors , Doxorubicin/toxicity , Enzyme Inhibitors/toxicity , Excitatory Amino Acid Agonists/pharmacology , Isoquinolines/antagonists & inhibitors , Isoquinolines/toxicity , Memantine/pharmacology , Staurosporine/antagonists & inhibitors , Staurosporine/toxicity , Androstadienes/pharmacology , Caspase 3/metabolism , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Chromones/pharmacology , Electrophysiology , Humans , L-Lactate Dehydrogenase/metabolism , Membrane Potentials/drug effects , Mitochondrial Membranes/drug effects , Morpholines/pharmacology , N-Methylaspartate/toxicity , Patch-Clamp Techniques , Tretinoin/pharmacology , Wortmannin
SELECTION OF CITATIONS
SEARCH DETAIL
...